December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.38 -0.11 (-0.67%)
Streaming Delayed Price Updated: 11:02 AM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Earnings Preview: Bausch & Lomb ↗
 
Via Benzinga
News headline image
Analyst Ratings for Bausch & Lomb ↗
 
Via Benzinga
News headline image
Analyst Ratings for Bausch & Lomb ↗
 
Via Benzinga
News headline image
9 Analysts Have This to Say About Bausch & Lomb ↗
 
Via Benzinga
News headline image
Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Looking Into Bausch & Lomb's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Bausch & Lomb's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Inflationary Factors And Slow Product Uptake Could Be Headwinds For Bausch + Lomb, Analyst Says ↗
 
Via Benzinga
News headline image
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Solidifies Leadership Team
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Recap: Bausch & Lomb Q1 Earnings ↗
 
Via Benzinga
News headline image
Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink ↗
Bausch + Lomb Corporation (NYSE: BLCO) has acquired Johnson & Johnson's (NYSE: JNJ) eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC)... 
Via Benzinga
News headline image
Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories ↗
New York Post 
Via Benzinga
News headline image
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis ↗
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE: 
Via Benzinga
News headline image
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
Via ACCESSWIRE
News headline image
Bausch + Lomb Will Acquire XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches PreserVision® AREDS 2 Formula Soft Gels Plus CoQ10 in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Key Leadership Changes
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.